The international steady glucose tracking marketplace was valued at US$6.32 billion in 2023 and is projected to reach US$13.06 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.40% from 2024 to 2032.
The file provides a thorough study of the segmented market through parts, end-users, international locations, and major corporations. The asset branch is irretrievably damaged in sensors, transmitters and receivers. The tip-user branch includes hospitals, homecare settings, and others. The geographical study covers 25 perspectives, including North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa, and the addition of the World, which includes graphic insights into specific international locations such as the United States, Canada, Germany, and the United States. , China and Brazil among others. Corporate research includes Dexcom Inc., Ypsomed AG, Abbott Laboratories, and Medtronic, Inc. Major gamers are included and it includes an outline, contemporary trends and income studies for each.
Diabetes is a factor in the following conditions that affect millions of people internationally:
- Currently, 537 million adults suffer from diabetes, and this number is expected to increase to 643 million by 2030 and 783 million by 2045.
- A majority of adults (44%) have undiagnosed diabetes, equivalent to approximately 240 million of the population. Most have type 2 diabetes.
- More than 75% of the population with diabetes lives in low- and middle-income international locations.
- It is estimated that more than 1.2 million children and young adults between 0-19 years of age suffer from type 1 diabetes.
- Diabetes was responsible for 6.7 million deaths in 2021.
- Diabetes contributed at least $966 billion to health care spending in 2021, which is 9% of total spending worldwide.
- High blood glucose during pregnancy affects one in six live births (21 million).
CGM Customers Through Nation:
- As of March 2023, approximately 2.4 million of the population in the United States are using static glucose displays.
- In December 2022, 200,000 UK patients were using non-invasive glucose tracking devices, up by a third since the spring.
- In 2023, 61.9% of women and 58% of men in Germany will take advantage of a continuous glucose monitor (CGM).
- In April 2023, the CGM penetration rate for type 1 diabetes in China was 6.9% and is expected to reach 38% by 2030.
- In 2021, approximately 33.9% of the Eastern population takes maximum advantage of Steady Glucose Display (CGM).
- According to a study by Mary Ann Liebert Inc., in 2023, more than half (53.1%) of the total group of type 1 diabetes patients in India will require a chronic glucose tracking (CGM) program.
China CGM Market
Diabetes has suddenly spread in the last decade due to changes in lifestyle and increasing age in the family. By 2045, it is projected to impact 629 million populations globally. China already has the largest area of diabetes sufferers (114.4 million) and is estimated to score 48%. Consistent with The Lancet Regional Condition, diabetes costs in China will increase from $250.2 billion to $460.4 billion during 2020–2030, with an annual growth rate of 6.32%.
Abbott Laboratories released a tool called Freestyle Libre 3 in April 2023. It is a handheld software that displays glucose readings in real time from a sensor above the arm. This allows diabetics to keep an eye on their condition by seeing their glucose readings on a rich, bright display.
Stable Glucose Tracking Corporate Information:
- The Dexcom Stello Glucose Biosensor gadget has been certified by the FDA for OTC sales, making it the first OTC stable glucose track in 2024.
- In January 2024, Medtronic’s MiniMed 780G gadget now features Simplera Sync, a non-returnable stable glucose monitor that gets rid of the need for a fingerstick. It offers an easy two-step insertion process and is part of the dimensions of the older Medtronic sensor, which an advanced person will enjoy.
- In 2023, Abbott Labs announced the release of the Freestyle Libre, its flagship CGM.
- In June 2023, I-SENS introduced CareSense Breeze, a compact glucose tracking software licensed by the South Korean Ministry of Health. It works for 15 days and has a calibration mechanism for accurate readings.
- In March 2023 – The Eversense E3 CGM gadget provides real-time glucose values and trends through a cellular app.
Main characteristics
| file component | main points |
| Wrong. of pages | 185 |
| forecast period | 2023-2032 |
| Estimated market value in 2023 (USD). | $6.32 billion |
| Estimated market cap by 2032 (USD). | $13.06 billion |
| compounded annual growth value | 8.4% |
| coated area | international |
Featured Companies:
- Dexcom Inc.
- Ypsomed AG
- Abbott Laboratories
- Senseonics Holdings, Inc.
- Nemoura Scientific, Inc.
- Medtronic, Inc.
- Tandem Diabetes Service
- Nova Biomedical
For more information about this file consult https://www.researchandmarkets.com/r/smd2df
About ResearchandMarkets.com
ResearchAndMarkets.com is the region’s leading supply of global market analysis stories and market intelligence. We provide you with real knowledge on global and regional markets, leading industries, dominating corporations, ancient goods and real trends.
-
International Stable Glucose Tracking Market